Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib

BACKGROUND: Epithelial ovarian cancer (EOC) is the most lethal disease among female genital malignant tumors. Peptidylarginine deiminase type II(PADI II) has been shown to enhance a variety of cancers carcinogenesis, including ovarian cancer. The purpose of this study was to investigate the biologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lidong, Zhang, Zhiwei, Zhang, Guoxiang, Wang, Ting, Ma, Yingchun, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504643/
https://www.ncbi.nlm.nih.gov/pubmed/32951601
http://dx.doi.org/10.1186/s12967-020-02528-0
_version_ 1783584671668371456
author Liu, Lidong
Zhang, Zhiwei
Zhang, Guoxiang
Wang, Ting
Ma, Yingchun
Guo, Wei
author_facet Liu, Lidong
Zhang, Zhiwei
Zhang, Guoxiang
Wang, Ting
Ma, Yingchun
Guo, Wei
author_sort Liu, Lidong
collection PubMed
description BACKGROUND: Epithelial ovarian cancer (EOC) is the most lethal disease among female genital malignant tumors. Peptidylarginine deiminase type II(PADI II) has been shown to enhance a variety of cancers carcinogenesis, including ovarian cancer. The purpose of this study was to investigate the biological role of PADI2 in ovarian cancer (OC) and the relative mechanism. METHODS: Gene Expression Profiling Interactive Analysis (GEPIA) (https://gepia.pku.cn/) and ONCOMINE (https://www.oncomine.org/) were used to analyze PADI2 Gene Expression data. The survival curve for the PADI2 gene was generated by using the online Kaplan–Meier mapping site (https://www.kmplot.com/). We conducted MTT assay, cloning formation assay and EdU cell proliferation assay to detect the cell activity of PADI2 knockdown A2780 and SKOV3 ovarian cancer cells treated with Olaparib. Cell migration and invasion were observed by would healing and transwell assay. The pathway changes after the treatment of PADI2 were detected by transcriptome sequencing and western blot. The role of PADI2 combined with Olaparib treatment in vivo was studied in nude mouse model bearing ovarian cancer tumor. RESULTS: We investigated the role of PADI2 on EOC in vitro and in vivo. PADI2 was upregulated in ovarian cancer samples and high PADI2 expression was correlated with poor outcome. Downregulating PADI2 suppressed colony formation, proliferation, migration and invasion of A2780 and SKOV3 cells. Furthermore, downregulating PADI2 and Olaparib combination treatment attenuated the viability, migration and invasion of A2780 and SKOV3 cells. We identified differentially expressed genes in A2780-shPADI2 and SKOV3-shPADI2 cell by transcriptome sequencing analysis and verified that downregulating PADI2 and Olaparib combination treatment suppresses EMT and JAK2/STAT3 signaling pathway in A2780 and SKOV3 cells in vitro and in vivo. CONCLUSIONS: Downregulation of PADI2 and Olaparib combination treatment attenuated the proliferation, migration and invasion of A2780 and SKOV3 cells by inhibiting the EMT through JAK2/STAT3 signaling pathway.
format Online
Article
Text
id pubmed-7504643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75046432020-09-23 Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib Liu, Lidong Zhang, Zhiwei Zhang, Guoxiang Wang, Ting Ma, Yingchun Guo, Wei J Transl Med Research BACKGROUND: Epithelial ovarian cancer (EOC) is the most lethal disease among female genital malignant tumors. Peptidylarginine deiminase type II(PADI II) has been shown to enhance a variety of cancers carcinogenesis, including ovarian cancer. The purpose of this study was to investigate the biological role of PADI2 in ovarian cancer (OC) and the relative mechanism. METHODS: Gene Expression Profiling Interactive Analysis (GEPIA) (https://gepia.pku.cn/) and ONCOMINE (https://www.oncomine.org/) were used to analyze PADI2 Gene Expression data. The survival curve for the PADI2 gene was generated by using the online Kaplan–Meier mapping site (https://www.kmplot.com/). We conducted MTT assay, cloning formation assay and EdU cell proliferation assay to detect the cell activity of PADI2 knockdown A2780 and SKOV3 ovarian cancer cells treated with Olaparib. Cell migration and invasion were observed by would healing and transwell assay. The pathway changes after the treatment of PADI2 were detected by transcriptome sequencing and western blot. The role of PADI2 combined with Olaparib treatment in vivo was studied in nude mouse model bearing ovarian cancer tumor. RESULTS: We investigated the role of PADI2 on EOC in vitro and in vivo. PADI2 was upregulated in ovarian cancer samples and high PADI2 expression was correlated with poor outcome. Downregulating PADI2 suppressed colony formation, proliferation, migration and invasion of A2780 and SKOV3 cells. Furthermore, downregulating PADI2 and Olaparib combination treatment attenuated the viability, migration and invasion of A2780 and SKOV3 cells. We identified differentially expressed genes in A2780-shPADI2 and SKOV3-shPADI2 cell by transcriptome sequencing analysis and verified that downregulating PADI2 and Olaparib combination treatment suppresses EMT and JAK2/STAT3 signaling pathway in A2780 and SKOV3 cells in vitro and in vivo. CONCLUSIONS: Downregulation of PADI2 and Olaparib combination treatment attenuated the proliferation, migration and invasion of A2780 and SKOV3 cells by inhibiting the EMT through JAK2/STAT3 signaling pathway. BioMed Central 2020-09-20 /pmc/articles/PMC7504643/ /pubmed/32951601 http://dx.doi.org/10.1186/s12967-020-02528-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Lidong
Zhang, Zhiwei
Zhang, Guoxiang
Wang, Ting
Ma, Yingchun
Guo, Wei
Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
title Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
title_full Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
title_fullStr Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
title_full_unstemmed Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
title_short Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
title_sort down-regulation of padi2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting jak2/stat3 pathway in vitro and in vivo, alone or in combination with olaparib
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504643/
https://www.ncbi.nlm.nih.gov/pubmed/32951601
http://dx.doi.org/10.1186/s12967-020-02528-0
work_keys_str_mv AT liulidong downregulationofpadi2preventsproliferationandepithelialmesenchymaltransitioninovariancancerthroughinhibitingjak2stat3pathwayinvitroandinvivoaloneorincombinationwitholaparib
AT zhangzhiwei downregulationofpadi2preventsproliferationandepithelialmesenchymaltransitioninovariancancerthroughinhibitingjak2stat3pathwayinvitroandinvivoaloneorincombinationwitholaparib
AT zhangguoxiang downregulationofpadi2preventsproliferationandepithelialmesenchymaltransitioninovariancancerthroughinhibitingjak2stat3pathwayinvitroandinvivoaloneorincombinationwitholaparib
AT wangting downregulationofpadi2preventsproliferationandepithelialmesenchymaltransitioninovariancancerthroughinhibitingjak2stat3pathwayinvitroandinvivoaloneorincombinationwitholaparib
AT mayingchun downregulationofpadi2preventsproliferationandepithelialmesenchymaltransitioninovariancancerthroughinhibitingjak2stat3pathwayinvitroandinvivoaloneorincombinationwitholaparib
AT guowei downregulationofpadi2preventsproliferationandepithelialmesenchymaltransitioninovariancancerthroughinhibitingjak2stat3pathwayinvitroandinvivoaloneorincombinationwitholaparib

Ejemplares similares